Nutrition additive supply chains 'nervous' as Suez blockage continues
Some seaborne deliveries are being rerouted or switched to air transportation as efforts to re-float stricken Ever Given container vessel move into fourth day
The logjam in the Suez canal caused by a stricken container ship wedged across the vital trade route has caused nervousness to human and animal nutrition additive supply chains, with some deliveries being switched to air transportation or put on hold, according to online trade platform and data provider, Kemiex.
Earlier this week, the 200,000-ton Panama-registered Ever Given, operated by shipping company Evergreen and bound for Rotterdam in the Netherlands from China became stuck in the Egyptian canal.
Efforts to re-float the vessel and free up the waterway are ongoing.
Stefan Schmidinger, partner at Kemiex told CPHI Online that three days after the incident, it remains unclear how long the waterway will be affected, with the best case scenario being a resolution next week, “but if cargo needs to be unloaded first this would multiply to three to six weeks in a base case.”
According to ship tracking platforms, an increasing number of vessels have changed course to take the route around Africa, causing a one-week delay to arrive at their destination, and a two-week delay for a full Asia-Europe round trip.
Schmidinger said this course of action results in a 10-20% reduction of carrier and container capacity on this lane, as well as additional fuel consumption and emissions, in a freight market that has been operating at its limits amid record rates for the last year.
“Human and animal nutrition additives, as well as other bulk chemicals, are being impacted directly, causing significant nervousness among supply chain managers,” he said. “A few new factory deliveries have reportedly been re-booked to air as the additional cost was secondary to a timely delivery, but more shippers have rushed to secure space or even put April deliveries on-hold.”
Schmidinger said the bottleneck could prove to be a boost to ‘niche’ freight trains connecting China-Europe typically costing less than air but moving cargo faster than sea.
Container freight rates have spiralled over the last few months amid a shortage of containers in Asia as Chinese exports recovered from the effects of the coronavirus pandemic. The Freightos FBX11 China-North Europe route index was marked at $7,500/FEU on March 25, up from around $2,500/FEU in November.
Schmidinger confirmed that as pharmaceutical ingredients are mostly airborne, the Suez incident has yet to cause any supply disruption for the sector.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance